Jpmorgan Chase & CO A Tyr Pharma Inc Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LIFE
# of Institutions
59Shares Held
37.1MCall Options Held
30.2KPut Options Held
3.1K-
Federated Hermes, Inc. Pittsburgh, PA14.7MShares$27.3 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.99MShares$5.56 Million0.0% of portfolio
-
Tikvah Management LLC Charlotte, NC2.46MShares$4.58 Million1.45% of portfolio
-
Logos Global Management LP San Francisco, CA2MShares$3.72 Million0.49% of portfolio
-
Checkpoint Capital L.P. San Francisco, CA1.74MShares$3.23 Million1.52% of portfolio
About aTYR PHARMA INC
- Ticker LIFE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,625,000
- Market Cap $53.2M
- Description
- aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...